JP2018115218A5 - - Google Patents

Download PDF

Info

Publication number
JP2018115218A5
JP2018115218A5 JP2018089165A JP2018089165A JP2018115218A5 JP 2018115218 A5 JP2018115218 A5 JP 2018115218A5 JP 2018089165 A JP2018089165 A JP 2018089165A JP 2018089165 A JP2018089165 A JP 2018089165A JP 2018115218 A5 JP2018115218 A5 JP 2018115218A5
Authority
JP
Japan
Prior art keywords
oral administration
formulation
disease
peak
administration according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018089165A
Other languages
English (en)
Japanese (ja)
Other versions
JP6657294B2 (ja
JP2018115218A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018115218A publication Critical patent/JP2018115218A/ja
Publication of JP2018115218A5 publication Critical patent/JP2018115218A5/ja
Application granted granted Critical
Publication of JP6657294B2 publication Critical patent/JP6657294B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018089165A 2009-11-12 2018-05-07 ニューロトロフィン模倣化合物およびこれらの塩の結晶形態 Active JP6657294B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US26067109P 2009-11-12 2009-11-12
US61/260,671 2009-11-12
US29427910P 2010-01-12 2010-01-12
US61/294,279 2010-01-12
US35079710P 2010-06-02 2010-06-02
US61/350,797 2010-06-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015200793A Division JP2016020380A (ja) 2009-11-12 2015-10-09 ニューロトロフィン模倣化合物およびこれらの塩の結晶形態

Publications (3)

Publication Number Publication Date
JP2018115218A JP2018115218A (ja) 2018-07-26
JP2018115218A5 true JP2018115218A5 (cg-RX-API-DMAC10.html) 2019-01-17
JP6657294B2 JP6657294B2 (ja) 2020-03-04

Family

ID=43992064

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012539022A Active JP5863663B2 (ja) 2009-11-12 2010-11-12 ニューロトロフィン模倣化合物およびこれらの塩の結晶形態
JP2015200793A Pending JP2016020380A (ja) 2009-11-12 2015-10-09 ニューロトロフィン模倣化合物およびこれらの塩の結晶形態
JP2018089165A Active JP6657294B2 (ja) 2009-11-12 2018-05-07 ニューロトロフィン模倣化合物およびこれらの塩の結晶形態

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2012539022A Active JP5863663B2 (ja) 2009-11-12 2010-11-12 ニューロトロフィン模倣化合物およびこれらの塩の結晶形態
JP2015200793A Pending JP2016020380A (ja) 2009-11-12 2015-10-09 ニューロトロフィン模倣化合物およびこれらの塩の結晶形態

Country Status (9)

Country Link
US (3) US9271986B2 (cg-RX-API-DMAC10.html)
EP (2) EP2498782B1 (cg-RX-API-DMAC10.html)
JP (3) JP5863663B2 (cg-RX-API-DMAC10.html)
CN (3) CN102740856B (cg-RX-API-DMAC10.html)
AU (1) AU2010319349B2 (cg-RX-API-DMAC10.html)
CA (2) CA3125909C (cg-RX-API-DMAC10.html)
ES (1) ES2712752T3 (cg-RX-API-DMAC10.html)
IN (1) IN2012DN05142A (cg-RX-API-DMAC10.html)
WO (1) WO2011060262A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011060262A1 (en) 2009-11-12 2011-05-19 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
JP2015535842A (ja) * 2012-09-27 2015-12-17 ファーマトロフィックス, インコーポレイテッド ニューロトロフィン模倣化合物の結晶形及びその塩
EP3302104B1 (en) * 2015-06-04 2020-09-30 Balchem Corporation Hydration control for choline salts
US11215532B2 (en) 2020-05-04 2022-01-04 Ford Global Technologies, Llc Methods and systems for exhaust gas recirculation system diagnostics
WO2026148059A1 (en) 2024-12-30 2026-07-09 Pharmatrophix, Inc. Salts and crystalline forms of lm11a31 and methods of use thereof

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3541130A (en) 1967-02-06 1970-11-17 Boehringer Sohn Ingelheim 1-(cyanophenoxy)-2-hydroxy-3-tert.-butylamine propanes
US4613676A (en) * 1983-11-23 1986-09-23 Ciba-Geigy Corporation Substituted 5-amino-4-hydroxyvaleryl derivatives
US4743607A (en) 1987-05-29 1988-05-10 Merrell Dow Pharmaceuticals Inc. Cardiotonic tricyclic imidazolones
WO1989010744A1 (en) 1988-05-02 1989-11-16 Naftchi N Eric Neurologically active compounds
US5028622A (en) 1988-05-06 1991-07-02 Ajinomoto Company, Inc. Administration of amino acids as treatment for neurodegenerative disorders
US5321029A (en) 1988-11-14 1994-06-14 Beecham-Wuelfing Gmbh & Co.K.G. Xanthines
CA2010531A1 (en) * 1989-03-06 1990-09-06 Werner Neidhart Amino acid derivatives
EP0536671B1 (de) 1991-10-07 1996-03-06 Hoechst Aktiengesellschaft Carbonsäureester-Schutzgruppen, ein Verfahren zu ihrer Herstellung, ihre Kopplung an eine funktionelle Gruppe sowie ihre Verwendung
US5608067A (en) 1993-12-09 1997-03-04 Afonso; Adriano 4-substituted pyrazoloquinoline derivatives
GB9402331D0 (en) 1994-02-07 1994-03-30 Univ Mcgill Nerve growth factor structural analogs and their uses
JPH08119922A (ja) 1994-10-21 1996-05-14 Torii Yakuhin Kk o−ピバロイル−チロシン誘導体
AU4117396A (en) * 1994-11-29 1996-06-19 Novartis Ag Morpholinoethylamide derivatives
JPH1081661A (ja) 1995-10-23 1998-03-31 Sankyo Co Ltd ヒドロキサム酸誘導体
US5958875A (en) 1996-03-29 1999-09-28 The Regents Of The University Of California Synthetic peptides derivatives with nerve growth factor-like neurotrophic activity
DE69736976T2 (de) 1996-03-29 2007-10-18 Trustees Of Boston University, Boston Mit Alzheimer Krankheit verknüpften Verfahren zur Diagnose, zur Herstellung von Medikamenten und zum Screenen von Substanzen sowie aus Beta-Amyloid abgeleiteten Peptiden
WO1997042168A1 (en) 1996-05-06 1997-11-13 Zeneca Limited Thio derivatives of hydroxamic acids
GB9613547D0 (en) 1996-06-27 1996-08-28 Pharmacia Spa Matrix metalloproteinase inhibitors
GB9616105D0 (en) 1996-07-31 1996-09-11 Univ Kingston TrkA binding site of NGF
GB9715962D0 (en) 1996-08-23 1997-10-01 Zeneca Ltd Sulfonamides
CN1100777C (zh) 1997-02-19 2003-02-05 伯莱克斯实验室公司 作为nos抑制剂的n-杂环衍生物
FR2762315B1 (fr) 1997-04-22 1999-05-28 Logeais Labor Jacques Derives d'amino-acides inhibiteurs des metalloproteases de la matrice extracellulaire et de la liberation du tnf alpha
US6117841A (en) 1997-05-30 2000-09-12 Warner-Lambert Company Substituted peptidylamine calcium channel blockers
US6342507B1 (en) 1997-09-05 2002-01-29 Isotechnika, Inc. Deuterated rapamycin compounds, method and uses thereof
US20020022657A1 (en) * 1998-02-11 2002-02-21 Francine Gervais Methods for modulating neuronal cell death
WO1999050264A1 (en) 1998-03-30 1999-10-07 Kyowa Hakko Kogyo Co., Ltd. Quinazoline derivatives
FR2783519B1 (fr) 1998-09-23 2003-01-24 Sod Conseils Rech Applic Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
CA2348946A1 (en) 1998-11-06 2000-05-18 Roche Diagnostics Gmbh Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases
CA2355137A1 (en) 1998-12-18 2000-06-29 Martyn Clive Pritchard Non-peptide nk1 receptors antagonists
US6583148B1 (en) 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
US6492380B1 (en) 1999-05-17 2002-12-10 Queen's University At Kingston Method of inhibiting neurotrophin-receptor binding
TWI275587B (en) 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
US6858577B1 (en) 1999-06-29 2005-02-22 Ortho-Mcneil Pharmaceutical, Inc. Indole peptidomimetics as thrombin receptor antagonists
DE19939910A1 (de) 1999-08-23 2001-03-01 Morphochem Ag Neue Verbindungen, die Tryptase-Aktivität hemmen
WO2001017953A1 (en) * 1999-09-08 2001-03-15 Guilford Pharmaceuticals Inc. Non-peptidic cyclophilin binding compounds and their use
WO2001042208A1 (en) 1999-12-08 2001-06-14 Teijin Limited Cycloamine ccr5 receptor antagonists
WO2001052843A1 (en) 2000-01-18 2001-07-26 Mcgill University β-TURN PEPTIDOMIMETIC CYCLIC COMPOUNDS
AR028606A1 (es) 2000-05-24 2003-05-14 Smithkline Beecham Corp Nuevos inhibidores de mmp-2/mmp-9
US6699989B1 (en) 2000-08-28 2004-03-02 B. Vithal Shetty Antiviral and antimicrobial guanidine or biguanidine derivatives
US6747735B2 (en) * 2000-12-13 2004-06-08 Spelman College Multiplex coherent raman spectroscopy detector and method
AU2002320490B2 (en) 2001-07-11 2008-10-02 Elan Pharmaceuticals, Inc. N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds
US20040248984A1 (en) 2001-08-29 2004-12-09 Josef Krieglstein Use of $g(b)-adrenoceptor agonists for the treatment of neurodegenerative diseases
WO2003030836A2 (en) * 2001-10-12 2003-04-17 Case Western Reserve University Neuronal regeneration
AR039555A1 (es) 2001-11-08 2005-02-23 Upjohn Co Derivados n,n'-sustituidos de 1,3-diamino-2-hidroxipropano
JP4584706B2 (ja) * 2002-05-03 2010-11-24 イスラエル インスティチュート フォー バイオロジカル リサーチ 中枢及び末梢神経系障害を治療するための方法及び組成物、並びにそれらに有用な新規の化合物
UA77526C2 (en) 2002-06-07 2006-12-15 Sanofi Aventis Substituted derivatives of 1-piperazineacylpiperidine, a method for the preparation thereof and their use in therapy
EP1553964A4 (en) 2002-09-25 2009-08-12 Georgia Tech Res Inst KETOAMID INHIBITORS IN CHRONIC NERVE DISEASES
WO2004031145A2 (en) 2002-10-02 2004-04-15 Bristol-Myers Squibb Company Lactam-containing diaminoalkyl, beta-aminoacids, alpha-aminoacids and derivatives thereof as factor xa inhibitors
US20040186044A1 (en) 2002-11-06 2004-09-23 Cosgaya Jose Miguel Modulation of myelination by interaction with P75 and TRK receptors
US20050154011A1 (en) 2003-02-20 2005-07-14 The Procter & Gamble Company Tetrahydroisoquinolnyl sulfamic acids
GB0304433D0 (en) 2003-02-27 2003-04-02 Xceleron Ltd Improvements relating to chemical libraries
WO2005044810A1 (en) 2003-10-30 2005-05-19 Janssen Pharmaceutica, N.V. Glyt2 modulators
CA2547283C (en) 2003-11-26 2010-11-09 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
US20060014790A1 (en) * 2004-01-21 2006-01-19 Varghese John Methods of treatment of amyloidosis using spirocyclohexane aspartyl-protease inhibitors
JP4775259B2 (ja) 2004-03-31 2011-09-21 味の素株式会社 アニリン誘導体
AU2005261487A1 (en) 2004-07-12 2006-01-19 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Amide derivatives as inhibitors of histone deacetylase
JP4194540B2 (ja) 2004-07-27 2008-12-10 キヤノン株式会社 画像形成装置
WO2006113097A2 (en) 2005-04-15 2006-10-26 The University Of North Carolina At Chapel Hill Methods of facilitating cell survival using neurotrophin mimetics
US20110230479A1 (en) 2005-04-15 2011-09-22 Longo Frank M Neurotrophin mimetics and uses thereof
EP2581440B1 (en) 2005-06-08 2016-03-16 The University of North Carolina At Chapel Hill Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics
EP1962855B1 (en) 2005-12-22 2013-08-21 Hydra Biosciences, Inc. Trpa1 inhibitors for treating pain
WO2008107365A1 (en) * 2007-03-02 2008-09-12 Medivir Ab New compounds
CA2754570A1 (en) 2009-03-06 2010-09-10 The University Of North Carolina At Chapel Hill Neurotrophin mimetics and uses thereof
WO2011060262A1 (en) 2009-11-12 2011-05-19 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
US20120322799A1 (en) 2009-11-30 2012-12-20 Pharmatrophix, Inc. Deuterated compounds useful for treating neurodegenerative diseases
JP2015535842A (ja) 2012-09-27 2015-12-17 ファーマトロフィックス, インコーポレイテッド ニューロトロフィン模倣化合物の結晶形及びその塩

Similar Documents

Publication Publication Date Title
JP2018024682A5 (cg-RX-API-DMAC10.html)
JP2010505958A5 (cg-RX-API-DMAC10.html)
JP2018035160A5 (cg-RX-API-DMAC10.html)
JP2015511958A5 (cg-RX-API-DMAC10.html)
JP2022515293A5 (cg-RX-API-DMAC10.html)
JP2007500757A5 (cg-RX-API-DMAC10.html)
MX2010013766A (es) Rasagilina para modificacion de enfermedad de parkinson.
CN109311832A (zh) 沃替西汀的帕莫酸盐及其晶型
JP2022539152A5 (cg-RX-API-DMAC10.html)
JP2012523395A5 (cg-RX-API-DMAC10.html)
EA016687B8 (ru) Производные циклопропиламида
JP2018521121A5 (cg-RX-API-DMAC10.html)
JP2013510874A5 (cg-RX-API-DMAC10.html)
JP2015522037A5 (cg-RX-API-DMAC10.html)
JP2013523846A5 (cg-RX-API-DMAC10.html)
AR112683A1 (es) Forma cristalina de base libre de levodopa, su sal de adición y composición farmaceutica que la comprende
MY189740A (en) Butylphthalide-telmisartan heterocomplex, preparation method and application thereof
RU2012136148A (ru) Новая кристаллическая форма производного циклопропилбензамида
JP2012509281A5 (cg-RX-API-DMAC10.html)
JP2011525185A5 (cg-RX-API-DMAC10.html)
JP2020502224A5 (cg-RX-API-DMAC10.html)
JP2008536844A5 (cg-RX-API-DMAC10.html)
IL266097B (en) Mono-orotate acid addition salt of r(–5–)–e(–2–)pyrrolidine––3ylvinyl)pyrimidine
JP2007530703A5 (cg-RX-API-DMAC10.html)
JP2013528627A5 (cg-RX-API-DMAC10.html)